Abstracts tagged "Myositis"

Abstract Number: 2075 • ACR Convergence 2025
Ferritin trends differentiate anti-MDA5 Dermatomyositis from anti-Jo1 Antisynthetase Syndrome
Silvia Grazzini¹, Edoardo Conticini¹, Marco Fornaro², Chiara Rizzo³, Lidia La Barbera³, Maria Rosa Pellico⁴, Stefano Stano⁵, Florenzo Iannone⁶, Giuliana Guggino³, Nicoletta Del Papa⁴, Luca Cantarini⁷ and Bruno Frediani⁷, ¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy, Siena, Italy, ²Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari, Italy., Bari, Italy, ³Rheumatology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) University of Palermo, Palermo, Italy, ⁴ASST Pini-CTO, Clinical Rheumatology Unit, Milano, Italy, ⁵⁶. Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy, ⁶Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ⁷Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University Hospital of Siena, Siena, Italy, Siena, Italy
Background/Purpose: Serum ferritin (FERR) is a recognized marker of immune activation and a key laboratory feature of anti-MDA5 Dermatomyositis (DM). It has been increasingly studied…
Abstract Number: 1663 • ACR Convergence 2025
Tocilizumab for acute exacerbation of rheumatic disease-related interstitial lung disease: A prospective real-world study
Wenwen Xu¹, Yiyangzi Ma², Shuang Ye³ and Qiong Fu², ¹Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China (People's Republic), ³Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Acute exacerbation (AE) of rheumatic disease-related interstitial lung disease (RD-ILD) is a severe and potentially life-threatening condition, while there remains no clear consensus of…
Abstract Number: 1203 • ACR Convergence 2025
Rituximab in Treatment Refractory vs Treatment Naive Anti-Signal Recognition Particle (SRP) Myositis – A Case Series
israrul haque¹ and Parasar Ghosh², ¹Institute of Postgraduate Medical Education and Research(IPGMER), KOLKATA, India, ²Dept of Clinical Immunology and Rheumatology, IPGMER & SSKM HospitalGovt of West Bengal, Kolkata, India, Kolkata, West Bengal, India
Background/Purpose: Anti-Signal Recognition Particle (Anti-SRP) Myositis is a form of Polymyositis. Available consensus guidelines recommend initial combination therapy of high dose corticosteroids and Methotrexate and…
Abstract Number: 0863 • ACR Convergence 2025
Myeloid Dendritic Cell Subsets Characterize Muscle of Inclusion Body Myositis Patients and Correlate with KLRG1+ and TBX21+ CD8+ T cells
Raphael Kirou¹, Iago Pinal-Fernandez¹, Maria Casal-Dominguez¹, Katherine Pak¹, Chiseko Ikenaga², Christopher Nelke³, Stefania Dell'orso¹, Faiza Naz¹, Shamima Islam¹, Gustavo Gutierrez-Cruz¹, Werner Stenzel⁴, Albert Selva-O'Callaghan⁵, José Milisenda⁶ and Andrew Mammen⁷, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²The University of Tokyo, Tokyo, Japan, ³Heinrich Heine University of Düsseldorf, Düsseldorf, Germany, ⁴Charite University, Berlin, Germany, ⁵Hospital Universitari Vall d'Hebron, Barcelona, Spain, ⁶Hospital Clinic de Barcelona, Barcelona, Spain, ⁷NIH, Bethesda, MD
Background/Purpose: Although inclusion body myositis (IBM) is an inflammatory myopathy, there are no effective immunomodulating agents, underlying the need for better understanding of its pathogenesis.…
Abstract Number: 0292 • ACR Convergence 2025
Patterns and Predictors of Longitudinal Trajectories of Pain in Individuals with Inflammatory Myopathies
Haley Zimmerman¹, Ethan Ritz², Kristin Wipfler³, Kaleb Michaud⁴ and Didem Saygin¹, ¹Rush University Medical Center, Chicago, IL, ²Rush Research Informatics Core, Rush University Medical Center, Chicago, IL, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Idiopathic inflammatory myopathies (IIM) have historically been considered a disease of painless weakness. However, recent studies indicate that most patients with IIM experience pain…
Abstract Number: 2073 • ACR Convergence 2025
Cell-free DNA as a Potential Marker of Muscle Involvement and Treatment Response in Myositis
Sabína Oreská¹, Kristina Svobodová¹, Lucia Vernerová¹, Dana Dlouhá², Hana Wunsch¹, Karel Pavelka¹, Jiri Vencovsky³, Ladislav Šenolt⁴, Michal Vrablik⁵, Jaroslav Alois Hubáček² and Michal Tomcik¹, ¹Institute of Rheumatology and Department of Rheumatology, ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Experimental Medicine Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ³Institute of Rheumatology, Praha ⁸, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵³rd Department of Internal Medicine, General University Hospital and ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by inflammatory muscle injury. Circulating cell-free DNA (cfDNA), including nuclear (cfnDNA) and mitochondrial (cfmtDNA) DNA, has been shown…
Abstract Number: 1537 • ACR Convergence 2025
Local Immune effector Cell-Associated Toxicity Syndrome (LICATS) in CAR T-cell treated patients with Autoimmune Disease
Melanie Hagen¹, Fabian Müller², Andreas Wirsching¹, Soraya Kharboutli³, Silvia Spoerl³, Christina Duesing⁴, Tobias Krickau⁵, Markus Metzler⁵, Simon Völkl³, Michael Aigner³, Sascha Kretschmann³, Ingrid Vasova³, Marc Saake⁵, Stefan Schliep⁵, Torsten Kubacki⁶, Nicolas Hunzelmann⁶, Laura Bucci¹, Jule Taubmann⁷, Christina Bergmann¹, Andrea-Hermina Györfi⁸, Sascha Dietrich⁹, Jörg Distler¹⁰, Ricardo Grieshaber-Bouyer¹¹, Andreas Mackensen¹² and Georg Schett¹³, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²University Hospital of Erlangen, Erlangen, Germany, ³Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Klinik für Rheumatologie, Düsseldorf, Germany, ⁵Friedrich-Alexander-Universität Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ⁶University and University Hospital Cologne, Cologne, Germany, Cologne, Germany, ⁷Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁸Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁹Heinrich Heine University Duesseldorf, University Hospital Duesseldorf, Duesseldorf, Germany, ¹⁰University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹¹University Hospital Erlangen, Erlangen, Germany, ¹²Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ¹³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment strategies for severe B-cell driven autoimmune diseases (AID) like Systemic Lupus erythematosus (SLE), Systemic…
Abstract Number: 1204 • ACR Convergence 2025
Validity and reliability of a new ultrasound-based semiquantitative echogenicity grading scale for myositis.
Takeshi Yoshida¹, Didem Saygin² and Jemima Albayda³, ¹Johns Hopkins Hospital, Baltimore, MD, ²Rush University Medical Center, Chicago, IL, ³Johns Hopkins University, Baltimore, MD
Background/Purpose: The Heckmatt grading scale has been widely used as a semiquantitative assessment method for grading muscle echo intensity (EI) on ultrasound; however, this was…
Abstract Number: 0862 • ACR Convergence 2025
In immune-mediated necrotising myopathy, anti-HMGCR antibodies inhibit HMGCR activity, leading to the sarcoplasmic accumulation of lipid droplets and myofibres necrosis
Margherita Giannini¹, Giulia Quiring², Mustapha Oulad-Abdelghani³, Béatrice Lannes¹, Yves Allenbach⁴, Olivier Benveniste⁵, Olivier Boyer⁶, Aleksandra Nadaj Pakleza¹, Bernard Geny⁷ and Alain Meyer⁸, ¹Strasbourg University Hospital, Strasbourg, France, ²University of Strasbourg, Strasbourg, France, ³IGBMC, Strasbourg, France, ⁴SORBONNE UNIVERSITE, Paris, France, ⁵Sorbonne Uniersite, Hopital de la Pitie-Salpetriere, Paris, France, ⁶University of Rouen, Rouen, France, ⁷UR ³⁰⁷², Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; FranceExplorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg;, Strasbourg, Alsace, France, ⁸Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Explorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, UR ³⁰⁷², Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; France, Strasbourg, Alsace, France
Background/Purpose: The aim of this study was to investigate whether in immune-mediated necrotising myopathy (IMNM), anti-HMGCR antibodies interfere with HMGCR activity and have a myopathic…
Abstract Number: 0290 • ACR Convergence 2025
Comparison of Organ Damage and Survival in Anti-synthetase Syndrome and Other Idiopathic Inflammatory Myopathies: An Analysis of Patients from Turkey
Ezgi Sahin¹, Omer Uludag², yasemin yalcinkaya³, Bahar Artim Esen⁴, Ahmet Gul³ and Murat Inanc³, ¹Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, ²Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ³Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey, ⁴Istanbul University, Istanbul, Istanbul, Turkey
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are rare autoimmune diseases characterized by muscle weakness, often involving other organs such as the skin, lungs, and heart. Defined…
Abstract Number: 2069 • ACR Convergence 2025
Concordance of low titer positive myositis-specific autoantibodies and myositis-associated autoantibodies on subsequent myositis panel testing.
Nikola Wilk¹, Jocelyn Hui Ching Chow², Ian Smith³, Ronald A. Booth⁴, Nancy Maltez¹, Catherine Ivory¹ and Jodi Warman-Chardon⁵, ¹Department of Medicine, Division of Rheumatology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ²Department of Medicine, Division of General Internal Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ³Department of Medicine, Division of Neurology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ⁴Department of Pathology and Laboratory Medicine, The Ottawa Hospital, University of Ottawa & Eastern Ontario Regional Laboratory Association, Ottawa, ON, Canada., Ottawa, ON, Canada, ⁵Department of Medicine, Division of Neurology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada. Department of Medicine and Cellular and Molecular Medicine, Children’s Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada., Ottawa, ON, Canada
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune connective tissue diseases that commonly affect multiple systems. Myositis-specific autoantibodies (MSA) and myositis-associated autoantibodies…
Abstract Number: 1271 • ACR Convergence 2025
Overcoming Obstacles to Care: Survey of Adult Patients with Idiopathic Inflammatory Myopathies (IIM)
Saloni Patolia¹, Carolina Alvarez², Jessica Grant³, Paul Mihas⁴, Todd Schwartz⁵, Galen Foulke⁶, Amanda Nelson⁵ and Astia Allenzara⁵, ¹UNC Rheumatology, Durham, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³Odum Institute for Reseach in Social Science, Chapel Hill, NC, ⁴Odum Institute for Reseach in Social Science, Chapel Hill, ⁵Thurston Arthritis Research Center, Chapel Hill, ⁶Penn State Health, Hershey, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are heterogenous autoimmune diseases requiring coordinated, patient-centered care. Understanding patient perspectives on diagnosis, treatment, health screening, and barriers to care…
Abstract Number: 1202 • ACR Convergence 2025
High Prevalence of Asymptomatic Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Validation of ACR/CHEST Risk Factors in a Hong Kong Cohort
Ka Ki Yam¹, Lucas Tsz Ho Luk¹, Weng Nga Lao², Chiu Wai Shirley Chan³, Dennis Tin Ho Chan⁴, Billy Tin Lok Lai⁵, Roy Tsz Chung Ho⁶, Vivian Hoi Shan Tang⁷, Ho So⁸ and Iris Tang⁹, ¹Department of Medicine & Geriatrics, Hong Kong, Hong Kong, ²Department of Medicine & Geriatrics, Kwong Wah Hospital, Hong Kong, Hong Kong, ³Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, ⁴Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong, ⁵Department of Medicine, Tseung Kwan O Hospital, Hong Kong, Hong Kong, ⁶Department of Medicine, Queen Elizabeth Hospital, Hong Kong, Hong Kong, ⁷Department of Medicine, North District Hospital, Hong Kong, Hong Kong, ⁸Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁹Department of Medicine, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Interstitial lung disease (ILD) is a common and severe complication of idiopathic inflammatory myopathies (IIM), adversely impacting clinical outcomes. While the ACR/CHEST guideline recommends…
Abstract Number: 0861 • ACR Convergence 2025
Identification of Anti-HDGFL1 as a Novel Autoantibody in Seronegative Idiopathic Inflammatory Myopathies
Xueting Yuan¹, Menghua Cai², Lu Gao², Chen Yu³, Jia Shi⁴, Yinghui Li², jiuliang Zhao¹, Dong Xu⁵, Chaojun Hu¹, Mengtao Li⁶, Xiaofeng Zeng⁷, jianmin Zhang² and Qian Wang⁶, ¹Peking Union Medical College Hospital (CAMS), Beijing, China (People's Republic), ²Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China (People's Republic), ³Peking Union Medical College Hospital, Dong Cheng Qu, Beijing, China (People's Republic), ⁴University of Washington, Seattle, WA, ⁵Peking Union Medical College Hospital, Dong Cheng District, China (People's Republic), ⁶Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ⁷Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, Beijing, China (People's Republic)
Background/Purpose: Myositis-specific autoantibodies (MSAs) play a crucial role in diagnosing and classifying idiopathic inflammatory myopathies (IIMs). However, approximately 30% of seronegative IIM patients may be…
Abstract Number: 0291 • ACR Convergence 2025
Acute onset inflammatory myositis: Clinical features and survival.
Gollakota Nandita¹, Madhuri Challa², Phani Kumar D³, Meghna Gavali⁴ and Liza rajasekhar⁵, ¹NIMS, Hyderabad, Hyderabad, Telangana, India, ²Nizams institute of medical sciences, hyderabad, Andhra Pradesh, India, ³NIMS, Hyderabad, Telangana, India, ⁴nizam's institute of medical sciences ,Hyderabad, Hyderabad, Telangana, India, ⁵Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are characterized by subacute onset symmetric proximal muscle weakness, with occasional extra-muscular involvement, leading to significant morbidity and mortality. Acute…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].